Work

Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population‐Based Longitudinal Cohort Study

Year: 2025

Type: article

Abstract: AIMS: Type 2 diabetes mellitus (T2DM) is recognized for increasing the risk of dementia; however, conclusive evidence supporting interventions to mitigate this risk remains elusive. This study endeavours to ascertain whether the glucagon-like peptide-1 receptor agonists (GLP-1RAs) correlate with reduced incidence of dementia. MATERIALS AND METHODS: The cohort comprised individuals initiating treatment with either GLP-1RAs or non-GLP-1RAs medications between 2013 and 2021. This study examined the association between GLP-1RAs and the risk of all-cause dementia. Propensity score-matched and Cox proportional hazard models were employed to calculate the adjusted hazard ratio (aHR) and confidence interval (CI) for the incidence of dementia. RESULTS: Among a cohort comprising 109,778 individuals, the use of GLP-1RA demonstrated a reduced risk of dementia compared with its non-use (aHR, 0.90; 95% CI, 0.83-0.97). Subgroup analyses stratified by different diabetic complications revealed significantly lower dementia incidence rates among GLP-1RAs users than among non-GLP-1RAs users. Individuals aged ≤ 75 years demonstrated a significant protective effect within GLP-1RAs users. CONCLUSIONS: The utilization of GLP-1 receptor agonists instead of non-GLP-1RAs medications demonstrated an association with a decreased incidence of dementia.

Source: Diabetes/Metabolism Research and Reviews

DOI: 10.1002/dmrr.70058

Authors: Hung‐Wen Cheng, Shun‐Fa Yang, Pei‐Lun Liao, Chiu‐Hsian Lee, Gwo‐Ping Jong

Institutions: Chung Shan Medical University Hospital, Chung Shan Medical University

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,780